Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Dysaesthesia, meaning abnormal burning, tingling, prickling, or painful skin sensations, is not recognized as a common side effect of Wegovy (semaglutide), whose most frequent reactions are nausea, diarrhea, vomiting, constipation, and injection site irritation. Still, some people taking it do report altered nerve sensations, which may relate to rapid weight loss, dehydration, low blood sugar, vitamin B12 or other nutrient deficiencies, or a separate underlying nerve condition, so there are several important factors to consider below, including timing, symptom patterns, and the warning signs that call for prompt medical attention.
Because unusual nerve sensations can point to causes far beyond your medication, describing exactly what you feel, and when it started, is the fastest way to understand what is happening. A free, instant, online symptom check asks the same questions a clinician would and gives you personalized insight into possible causes in just a few minutes. Use it to clarify your next step, whether that means monitoring at home, adjusting your care plan with your prescriber, or seeking urgent evaluation.
Last reviewed for medical accuracy: 09/14/2026
Is dysaesthesia a common side effect of Wegovy? And why does Wegovy cause dysaesthesia? Below you’ll find clear, evidence-based information drawn from prescribing labels, clinical trial data and expert guidance. This overview explains what dysaesthesia is, how often it’s reported with Wegovy, possible reasons it may occur, and what to do if you notice unusual sensations.
Dysaesthesia (also spelled dysesthesia) refers to abnormal, often unpleasant sensations such as:
These symptoms can affect any part of the body but most commonly involve hands, feet, arms and legs. They are different from pain alone, and they may occur without an obvious trigger.
Wegovy® (semaglutide 2.4 mg once weekly), approved by the FDA for chronic weight management, belongs to a class of medications called GLP-1 receptor agonists. It works by:
Because it influences digestion, appetite and metabolism, Wegovy’s most frequently reported side effects are gastrointestinal (GI).
In large clinical trials (STEP 1–4), the most frequent side effects (occurring in ≥ 5 percent of people) were:
Neurologic complaints such as headache and dizziness are listed, but specific reports of dysaesthesia were very rare.
No. Based on the available data:
Although dysaesthesia is uncommon with Wegovy, here are several plausible explanations for why some people might experience it:
Rapid weight loss and nutritional shifts
Blood sugar fluctuations
Gastrointestinal changes
Direct or indirect nerve effects
Coincidental onset
If you notice unusual tingling, burning or numbness, consider these steps:
Monitor and document
• Note when the sensation began, which areas are affected, and any factors that make it better or worse.
• Keep track of concurrent symptoms—GI changes, blood sugar highs/lows, mood shifts or sleep quality.
Assess nutrition
• Ensure you’re getting balanced meals with adequate B-vitamins, magnesium and other nerve-supporting nutrients.
• If you have persistent diarrhea or malabsorption, discuss testing for deficiencies with your doctor.
Check blood sugar patterns (if diabetic)
• Review your glucose log for any sudden drops or spikes that coincide with the onset of dysaesthesia.
• Work with your healthcare provider to adjust diet or medications if needed.
Lifestyle adjustments
• Gentle stretching, supportive footwear or ergonomic modifications can relieve pressure on nerves.
• Low-impact activities such as swimming or yoga may improve circulation without overstressing joints.
Medication review
• Some drugs (certain antibiotics, statins, chemotherapy agents) can cause neuropathic symptoms.
• Your provider may evaluate all current medications to identify potential contributors.
When to seek medical help
• Sudden, severe numbness or weakness
• Loss of muscle control or balance
• Signs of a serious allergic reaction (rash, swelling, difficulty breathing)
• Any symptoms that are life threatening or significantly interfere with daily life
Before making any changes, always talk to your doctor. If you’re unsure whether your symptoms could be related to Wegovy or another health issue, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
If you experience dysaesthesia or any other troubling symptom while taking Wegovy, speak to a doctor—especially if you have weakness, balance problems or loss of function. Your healthcare team can help determine the cause and guide you toward the right solution.
(References)
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, Quiroga M, Rosenstock J, Garvey WT, STEP UP trial group. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025 Nov;13(11):949-963. doi: 10.1016/S2213-8587(25)00226-8. Epub 2025 Sep 14. PMID: 40961952.
* Lingvay I, Bergenheim SJ, Buse JB, Freitas P, Garvey WT, Harder-Lauridsen NM, Rosenstock J, Sahu K, Wharton S, STEP UP T2D trial group. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025 Nov;13(11):935-948. doi: 10.1016/S2213-8587(25)00225-6. Epub 2025 Sep 14. PMID: 40961953.
* Santulli G. From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovasc Diabetol Endocrinol Rep. 2025 Oct 6;11(1):31. doi: 10.1186/s40842-025-00245-5. Epub 2025 Oct 6. PMID: 41053816; PMCID: PMC12498447.
* Ahern S. Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide. Cureus. 2025 Oct;17(10):e94126. doi: 10.7759/cureus.94126. Epub 2025 Oct 8. PMID: 41210042; PMCID: PMC12594042.
* Laroche ML, Géniaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. Eur J Clin Pharmacol. 2026 May 22;82(6). doi: 10.1007/s00228-026-04079-7. Epub 2026 May 22. PMID: 42168638; PMCID: PMC13194321.
* Quarenghi M, Stanga A, Bergamaschi A. Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report. J Am Coll Emerg Physicians Open. 2026 Aug;7(4):100427. doi: 10.1016/j.acepjo.2026.100427. Epub 2026 May 29. PMID: 42256775; PMCID: PMC13241993.
* Popa Ilie IR, Ghibu S, Butuca A, Dobrea CM, Frum A, Homorodean C, Chis AA, Morgovan C. Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data. Pharmaceuticals (Basel). 2026 May 31;19(6). doi: 10.3390/ph19060876. Epub 2026 May 31. PMID: 42356493; PMCID: PMC13305957.
* Al-Zawawi AS. Oral Adverse Effects of Semaglutide Therapy: A Narrative Review. J Int Soc Prev Community Dent. 2024 Jul-Aug;16(4):331-340. doi: 10.4103/jispcd.jispcd_5_26. Epub 2026 Jul 9. PMID: 42730115; PMCID: PMC13568709.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.